生物试剂
>
生化试剂
>
信号通路
> Motixafortide
加入收藏 取消收藏

Motixafortide  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：5mg 10mg 25mg 50mg 100mg in glass bottle
溶解性：溶于水（100mg/mL 超声），溶于DMSO（≥100mg/mL）
产品描述：基本信息 产品编号： M10927 产品名称： Motixafortide CAS: 664334-36-5   储存条件 粉末 -20℃ 四年     分子式： C97H144FN33O19S2 溶于液体 -80℃ 6个月 分子量： 2159.52 -20℃ 1个月 化学名：  4F-benzoyl-TN14003 Solubility (25°C)：   体外:   DMSO   Ethanol   Water 100mg/mL (46.3mM) 体内(现配现用):   ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 0.4631mL 2.3153mL 4.6307mL 5mM 0.0926mL 0.4631mL 0.9261mL 10mM 0.0463mL 0.2315mL 0.4631mL   生物活性 产品描述 一种新型的CXCR4拮抗剂，IC50约为1nM。 靶点 CXCR4 ~1nM (IC50)   体外研究 Motixafortide (BKT140) displays selective toxicity toward AmL and MM cells.Treatment with Motixafortide (BKT140) can overcome IL-6 dependent proliferation and survival of ARH77 MM cells.Motixafortide (BKT140) specifically triggers CXCR4-dependent cell death in leukemia and MM cells.Motixafortide (BKT140) stimulates apoptotic cell death in leukemia and MM cells. 体内研究 Subcutaneous injections of Motixafortide (BKT140) significantly reduces,in a dose-dependent manner,the growth of human acute myeloid leukemia and multiple myeloma xenografts.Tumors from animals treated with Motixafortide (BKT140) are smaller in size and weights,had larger necrotic areas and high apoptotic scores.   推荐实验方法(仅供参考) 细胞实验:   Hematopoietic cancer cells are incubated with different concentrations of Motixafortide (BKT140) or AMD3100 for 24 hours.Motixafortide (BKT140) is treated with 1M hydrochloric acid (HCL) to achieve a pH of 2.7 to 3 at room temperature for 30 minutes and the pH is adjusted to 7 using concentrated NaOH.Proteinase K is added to Motixafortide (BKT140) at a final concentration of 100mg/mL,incubated at 37℃ for 1 hour,and inactivated by heat treatment (65℃ for 30 minutes).After incubation,cells are stained with propidium iodide and the percent of viable PI-negative cells in culture is determined.   动物实验:   Mice:Severe combined immune-deficient (SCID)/beige mice (C.B-17/IcrHsd-SCID-bg) are used in the study.NB4 cells resuspended in PBS are injected subcutaneously into the flanks of the mice (200μL per mouse containing 5×106 cells).Tumor growth is monitored daily,and mice are randomized to drug-treated or control PBS-treated groups (10 mice per group) when the tumor size (width×length) reaches 0.04 cm2.BKT140 is administered subcutaneously at a dose of 200μg per mouse each day for 5 days.
保存条件：-20℃

猜你喜欢